Abstract▲ Oral cinacalcet hydrochloride (HCl)[Sensipar®, Mimpara®] is the first in a new
class of therapeutic agents, the calcimimetics, and has a novel mechanism of action. It …

Cinacalcet HCl (AMG 073) is an investigational oral calcimimetic drug currently being
evaluated for the treatment of primary and secondary hyperparathyroidism (HPT) …

Secondary hyperparathyroidism (SHPT) develops as a result of impaired calcium
homeostasis when the failing kidneys disturb the complicated interactions between …

Hyperparathyroidism is characterized by high levels of circulating calcium due to an
increased secretion of parathyroid hormone (PTH) by one or more of the parathyroid glands …

Management of secondary hyperparathyroidism is challenging with traditional therapy. The
calcimimetic cinacalcet HCl acts on the calcium-sensing receptor to increase its sensitivity to …

BACKGROUND:: Uncontrolled hyperparathyroidism (HPT), particularly HPT resulting from
chronic kidney disease (CKD), is associated with significant morbidity and cardiovascular …

Cinacalcet hydrochloride is a calcimimetic agent that activates the calcium‐sensing receptor
on the surface of parathyroid cells and inhibits parathyroid hormone (PTH) secretion. To …

Secondary hyperparathyroidism (SHPT) is associated with parathyroid gland hyperplasia,
increased parathyroid hormone (PTH) production and secretion, disturbed bone and mineral …

The calcium sensing receptor (CaSR) is expressed in cells secreting calcium-regulating
hormones, in cells involved in calcium transport and in many other tissues, with an as yet not …

Currently,> 300,000 patients with end-stage renal disease require dialysis. Secondary
hyperparathyroidism is a serious complication of end-stage renal disease and can lead to …